Browse the toolkit beneath workflows. The mechanism branch runs mechanism -> architecture -> component, while the technique branch runs from high-level approaches down to concrete methods.
13 items matching 1 filter
Mechanism Branch
Layer 1
Mechanisms
Top-level concepts: biophysical action modes such as heterodimerization, photocleavage, or RNA binding.
Layer 2
Architectures
Arrangements that realize or deploy mechanisms, including switches, construct patterns, and delivery strategies.
Layer 3
Components
Low-level parts and sequence-defined elements used inside architectures, including protein domains and RNA elements.
Technique Branch
Layer 1
Approaches
High-level engineering practices such as computational design, directed evolution, sequence verification, and functional assay.
Layer 2
Methods
Concrete methods used to design, build, verify, or characterize engineered systems.
Showing 1-13 of 13
This tool is a genetically encoded optogenetic switch that uses light to regulate biological function. The supplied evidence supports its use to control central metabolic flux in Escherichia coli and to drive spatiotemporally controlled shape change in yeast with pulses of dim blue light.
The upstream summary states that the review abstract explicitly covers engineered cells with synthetic DNA circuits.
The artificial differentiation system is a light-tunable construct pattern in budding yeast based on optogenetically driven genetic rewiring. It is designed to generate stable microbial consortia with user-defined composition in space and time from a single strain and supports dynamic control of consortium composition in continuous culture.
Here, we constructed lysosome-localized optogenetic actuators, named lyso-NpHR3.0, lyso-ArchT, and lyso-ChR2, to achieve optogenetic manipulation of lysosomes.
This tool is an optogenetic actuator used to control Rho activity with local and reversible effects on cellular contractility. In the cited 2023 study, it was applied to probe DLC1-dependent regulation of Rho signaling at focal adhesions and the plasma membrane.
Optogenetic control of apical constriction is an engineering method that uses light to drive apical constriction and thereby induce synthetic morphogenesis in mammalian tissues. The available evidence supports this method as a light-responsive approach for reshaping tissue architecture.
Optogenetic control of mitochondria-lysosome contacts is an engineering method that uses light to modulate contacts between mitochondria and lysosomes. In the cited 2022 Nature Communications study, this manipulation enabled light-activated mitochondrial fission.
TRIM21-nanobody chimeras are engineered Trim-Away constructs that fuse TRIM21 activity to nanobody-based target recognition. In the cited 2020 work, these chimeras were described as highly active and were further adapted for optogenetic control of targeted protein degradation.
The wireless-powered optogenetic designer cell implant is a delivery harness reported in Nature Communications (2014) to enable mind-controlled transgene expression. The available evidence identifies a wireless-powered optogenetic implant concept coupled to transgene regulation, but does not provide construct-level or device-level detail here.
The recent generation of optogenetic tools and biosensors that control and detect active Rho has overcome some of these challenges and is helping to elucidate the role of RhoA in cytokinesis.
Light-controllable designer cells are optogenetically engineered mammalian cells whose behavior is regulated by light. The available evidence supports their use as a precise and noninvasive control modality in therapeutic synthetic biology.
Split recombinases are recombinase enzymes partitioned into inactive fragments that can be reactivated in light-controlled inducible recombination systems. The supplied evidence indicates that optogenetic switches mediate reactivation of the split fragments to control recombination.
Genetically encoded Ca(2+) indicators (GECIs), light-gated channels, and exogenous receptors are being developed to selectively read out and stimulate astrocyte activity. Our review discusses emerging perspectives on: (ii) new pharmacogenetic and optogenetic approaches to activate specific Ca(2+) signaling pathways in astrocytes